DNA-cell-binding (DCB) assay for suspected carcinogens and mutagens

Mutation Research
|June 1, 1981
PubMed

Insights

The novel DNA-cell-binding (DCB) assay effectively screens for carcinogens and mutagens. This rapid test shows high agreement with animal studies, offering a reliable method for chemical safety assessment.

Area of Science:

  • Toxicology
  • Molecular Biology
  • Biochemistry

Background:

  • Carcinogens induce DNA damage, forming adducts with nucleic acids and proteins.
  • These adducts can involve proteins in prokaryotic and eukaryotic cell membranes.
  • Increased DNA attachment to cells indicates potential carcinogenicity.

Purpose of the Study:

  • To introduce and validate the DNA-cell-binding (DCB) assay for screening potential carcinogens and mutagens.
  • To compare the DCB assay's performance against established animal assays and other rapid methods.
  • To assess the combined predictive power of the DCB assay with DNA-protein adduct measurements.

Main Methods:

  • Developed the DNA-cell-binding (DCB) assay based on DNA-macromolecule interactions.
  • Tested approximately 280 chemicals, including 130 with known carcinogenic status.
  • Compared DCB assay results with traditional animal carcinogenicity assays.
  • Evaluated combined DCB assay and DNA-protein adduct data for enhanced predictability.

Main Results:

  • The DCB assay demonstrated high agreement (96%) with animal assays for predicting carcinogenicity.
  • The DCB assay proved superior to other macromolecular complex detection methods.
  • Combining DCB assay results with DNA-protein adduct measurements in human cells increased predictability to 100%.

Conclusions:

  • The DCB assay is a reliable and efficient method for screening potential carcinogens and mutagens.
  • It offers a favorable alternative to existing rapid screening techniques.
  • The DCB assay, alone or combined with other methods, is recommended for evaluating chemical carcinogenic potential.